You are herePublications


Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M, Bennie M, Barbui C, Wttermark B, Sturkenboom M, De Ponti F. Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data accross Europe. PLoS ONE 2013;8(11):381208.

Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER, Sturkenboom M, de Ponti F. Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. Drug Saf 2013 Jun;36(6):467-79.

Raschi E, Poluzzi E, Koci A, Moretti U, Sturkenboom M, de Ponti F. Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacoviglinace database. J Pharmacovigilance 2013;1:104.

Di Martino GP, Masetti M, Ceccarini L, Cavalli A, Recanatini M. An Automated Docking Protocol for hERG Channel Blockers. J Chem Inf Model 2013; 53(1):159-75

Warnier MJ, Blom MT, Bardai A, Berdowksi J, Souverein PC, Hoes AW, Rutten FH, de Boer A, Koster RW, de Bruin ML, Tan HL. Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study. PLoS One 2013;8:e65638

Bardai A, Amin AS, Blom MT, Bezzina CR, Berdowski J, Langendijk PNJ, Beekman L, Klemens CA, Souverein PC, Koster RW, de Boer A, Tan HL. Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. Eur Heart J 2013;34:1506-16

Blom MT, Warnier MJ, Bardai A, Berdowski J, Koster RW, Souverein PC, Hoes AW, Rutten FH, de Boer A, de Bruin ML, Tan HL. Reduced in-hospital survival rates of out-of-hospital cardiac arrest victims with obstructive pulmonary disease. Resuscitation 2013;84:569-574

Ceccarini L, Masetti M, Cavalli A, Recanatini M. Ion Conduction through the hERG Potassium Channel. PLoS One 2012; 7(11): e49017

Molokhia M, De Ponti F, Behr E, Trifirò G, Sturkenboom M. Academic output from EU-funded health research projects. The Lancet, Vol 380, Issue 9857, 1903-1904, 1 December 2012.

Cavalli A, Buonfliglio R, Ianni C, Masetti M, Ceccarini L, Caves R, Chang MW, Mitcheson JS, Roberti M, Recanatini M. Computational design and discovery of "minimally structured" hERG blockers. J Med Chem. 2012 Apr 26;55(8):4010-4.

Raschi E, Poluzzi E, Koci A, Boriani G, De Ponti F. QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. Br J Clin Pharmacol. 2011 Nov;72(5):839-41.

Blom MA, Bardai A, van Munster BC, Nieuwland MI, de Jong H, van Hoeijen DA, Spanjaart AM, de Boer A, de Rooij SE, Tan HL. Differential changes in QTc duration during in-hospital haloperidol use. PLoS One 2011;6(9):e23728.

Sturkenboom M, Molokhia M. ARITMO Project: Arrhythmia-related risks of drugs. BJCN 2010;5(5):255.